What do systematic reviews say?

Rituximab vs placebo

Rituximab as 'switching' may leads to lower relapse measured by clinical assessment over 12 months compared with placebo (low certainty).

• Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
  OR 0.38 [0.16, 0.93]
  1 study · 104 participants
  Low